No abstract available
MeSH terms
-
Adult
-
Aged
-
COVID-19
-
Coronavirus Infections / complications
-
Coronavirus Infections / immunology
-
Coronavirus Infections / mortality
-
Coronavirus Infections / physiopathology*
-
Crotonates / therapeutic use
-
Dimethyl Fumarate / therapeutic use
-
Female
-
Fingolimod Hydrochloride / therapeutic use
-
Glatiramer Acetate / therapeutic use
-
Humans
-
Hydroxybutyrates
-
Immunocompromised Host*
-
Immunosuppressive Agents / therapeutic use*
-
Interferons / therapeutic use
-
Lymphopenia / chemically induced
-
Male
-
Middle Aged
-
Multiple Sclerosis, Chronic Progressive / complications
-
Multiple Sclerosis, Chronic Progressive / drug therapy*
-
Multiple Sclerosis, Chronic Progressive / physiopathology
-
Multiple Sclerosis, Relapsing-Remitting / complications
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
-
Multiple Sclerosis, Relapsing-Remitting / physiopathology
-
Nitriles
-
Northwestern United States
-
Nursing Homes
-
Oregon
-
Pandemics
-
Pneumonia, Viral / complications
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / mortality
-
Pneumonia, Viral / physiopathology*
-
Severity of Illness Index
-
Toluidines / therapeutic use
-
Travel
-
Washington
Substances
-
Crotonates
-
Hydroxybutyrates
-
Immunosuppressive Agents
-
Nitriles
-
Toluidines
-
teriflunomide
-
Glatiramer Acetate
-
Interferons
-
Dimethyl Fumarate
-
Fingolimod Hydrochloride